NS 1209

Drug Profile

NS 1209

Alternative Names: SPD 502

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator NeuroSearch
  • Class Amino acids; Antiepileptic drugs; Neuroprotectants; Oximes; Small molecules
  • Mechanism of Action AMPA receptor antagonists; Metabotropic glutamate receptor 5 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Neuropathic pain; Status epilepticus; Stroke

Most Recent Events

  • 21 Jun 2007 NeuroSearch is seeking a partner to continue development of NS 1209 for Neuropathic pain and Status epilepticus (http://www.neurosearch.com)
  • 13 Jun 2007 Discontinued - Phase-II for Stroke in Europe (IV)
  • 31 Aug 2005 Phase-I/II clinical trials in Neuropathic pain in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top